Paul Sorajja, MD

Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital
Allina Health Minneapolis Heart Institute
Minneapolis, Minnesota, United States

Dr. Sorajja has expertise in valvular and structural heart disease and interventional cardiology. Dr. Sorajja is the national P.I. for multiple clinical trials, including TRILUMINATE, SUMMIT-MAC, EXPAND II, vDyne EFS, and SOAR-EFS. He is highly active in intellectural property development, and has published over 300 manuscripts and book chapters.
 

Disclosure information not submitted.

Presentation(s):

• Anatomy, Indications and Outcomes for Tricuspid TEER for Incomplete Coaptation

  Saturday, March 7, 2026
  8:16 AM - 8:24 AM EST

• Panel Discussion | How to Select Best Candidates for Tricuspid Repair/Replacement

  Saturday, March 7, 2026
  9:12 AM - 9:40 AM EST

• Live Case Broadcasting From Piedmont | Atlanta, Georgia

  Saturday, March 7, 2026
  9:40 AM - 10:25 AM EST

• Updates from the TRILUMINATE Pivotal Study Update and Challenges for Commercial Adoption of Transcatheter Tricuspid Repair

  Saturday, March 7, 2026
  10:25 AM - 10:33 AM EST

• Panel Discussion | Are we Ready for Repair and Replacement of Tricuspid Disease?

  Saturday, March 7, 2026
  11:13 AM - 11:30 AM EST

• TMVR Devices | AltaValve Update

  Sunday, March 8, 2026
  3:56 PM - 4:04 PM EST

• Panel Discussion | Percutaneous Mitral Valve Replacement | Preliminary Data Reports – Technologies

  Sunday, March 8, 2026
  4:20 PM - 4:40 PM EST